RA CAPITAL MANAGEMENT, L.P. recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
200 BERKELEY STREET, 18TH FLOOR Boston, MA 02116
As of the latest 13F report, the guru’s equity portfolio contained 70 stocks valued at a total of $4.93Bil. The top holdings were ASND(17.23%), PCVX(5.70%), and AVTE(4.91%).
According to GuruFocus data, these were RA CAPITAL MANAGEMENT, L.P.’s top five trades of the quarter.
Forma Therapeutics Holdings Inc
The guru sold out of their 9,011,651-share investment in NAS:FMTX. Previously, the stock had a 3.84% weight in the equity portfolio. Shares traded for an average price of $19.99 during the quarter.
On 02/18/2023, Forma Therapeutics Holdings Inc traded for a price of $20.01 per share and a market cap of $957.69Mil. The stock has returned 13.82% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Forma Therapeutics Holdings Inc has a price-book ratio of 2.31 and a EV-to-Ebitda ratio of -3.15.
Vaxcyte Inc
During the quarter, RA CAPITAL MANAGEMENT, L.P. bought 3,572,356 shares of NAS:PCVX for a total holding of 8,153,559. The trade had a 3.53% impact on the equity portfolio. During the quarter, the stock traded for an average price of $47.95.
On 02/18/2023, Vaxcyte Inc traded for a price of $44.22 per share and a market cap of $3.49Bil. The stock has returned 114.45% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Vaxcyte Inc has a price-book ratio of 7.46 and a EV-to-Ebitda ratio of -18.68.
Biogen Inc
RA CAPITAL MANAGEMENT, L.P. reduced their investment in NAS:BIIB by 404,657 shares. The trade had a 2.3% impact on the equity portfolio. During the quarter, the stock traded for an average price of $282.44.
On 02/18/2023, Biogen Inc traded for a price of $278.38 per share and a market cap of $40.22Bil. The stock has returned 32.17% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Biogen Inc has a price-earnings ratio of 13.30, a price-book ratio of 2.99, a EV-to-Ebitda ratio of 9.28 and a price-sales ratio of 4.01.
The price-to-GF Value ratio is 1.21, earning the stock a GF Value rank of 3.
Inhibrx Inc
The guru established a new position worth 3,853,867 shares in NAS:INBX, giving the stock a 1.93% weight in the equity portfolio. Shares traded for an average price of $29.39 during the quarter.
On 02/18/2023, Inhibrx Inc traded for a price of $23.95 per share and a market cap of $1.04Bil. The stock has returned 9.16% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Inhibrx Inc has a EV-to-Ebitda ratio of -9.20 and a price-sales ratio of 199.33.
Ascendis Pharma A/S
RA CAPITAL MANAGEMENT, L.P. reduced their investment in NAS:ASND by 610,721 shares. The trade had a 1.59% impact on the equity portfolio. During the quarter, the stock traded for an average price of $122.13.
On 02/18/2023, Ascendis Pharma A/S traded for a price of $116.65 per share and a market cap of $6.65Bil. The stock has returned 1.67% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Ascendis Pharma A/S has a price-book ratio of 14.88, a EV-to-Ebitda ratio of -13.72 and a price-sales ratio of 180.90.
The price-to-GF Value ratio is 0.13, earning the stock a GF Value rank of 2.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
